Skip to content
Clinical Trial Events
ISPOR Europe 2026

Panel Expanded Value Measures track

Are HTA and Health Funding Systems Failing to Incentivise Investment in Disease Prevention?

Tue, Nov 10, 2026 · 1:45–2:45 PM CET Hall K2, Level -2, Austria Center Vienna

About this session

ISSUE: European health systems consistently state that prevention is a priority, yet funding and evaluation arrangements historically prioritise treating disease. Prevention interventions generate benefits over long time horizons across sectors. Benefits may not be fully recognised within existing HTA and funding structures, which typically assess value based on direct patient outcomes and within annual spending cycles.

Speakers